Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.

Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same period in 2010.  Increased operating expenses for the fourth quarter of 2011 and for the full calendar year compared to the same periods in 2010 are primarily due to increased research and development expenses associated with our Phase 2b PEARL-SC clinical study in patients with Systemic Lupus Erythematosus, or lupus, and our VISTA-16 clinical study in patients with Acute Coronary Syndrome, or ACS.

Anthera ended the fourth quarter of 2011 with approximately $67.4 million in cash and cash equivalents and short-term investments.  This is compared to $93.3 million in cash and cash equivalents and short-term investments for the third quarter ended September 30, 2011.

In conjunction with the release of the fourth quarter 2011 financial report, Anthera will host a conference call at 1 p.m. Eastern Time today, February 21, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 47038854. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854.  The audio replay will be available until February 28, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • In December 2011, the VISTA-16 Data Safety Monitoring Board (
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
    (Date:10/22/2014)... 22, 2014  Quest Diagnostics (NYSE: DGX ... today announced that its Board of Directors has elected ... effective December 1, 2014. Including Dr. Leiden, the Board ... Chairman, President and CEO of Vertex Pharmaceuticals.   Dr. ... commercial experience in the pharmaceutical and biotechnology industries as ...
    (Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
    Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
    ... 2011  Seventeen of the 19 medical-surgical suppliers and healthcare ... 25 for 2011 work with GHX to automate and ... them achieve high-quality patient care at optimal economic cost. ... and providers recognized by Gartner in the Top 25 ...
    ... 2011 ULURU Inc. (NYSE AMEX: ... of the previously announced European license for Altrazeal®, with a ... Zealand. Extending the European territory to include ... is a common registration process and the marketing strategy and ...
    Cached Medicine Technology:GHX Salutes 17 Healthcare Organizations That Use Its Technology for Inclusion on a Leading Analyst Firm's 2011 Healthcare Supply Chain Top 25 List 2ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand 2ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand 3
    (Date:10/22/2014)... 2014 The Louis W. ... dedicated to distribute health information technology innovation to ... announced the development of six key guiding principles ... receiving healthcare. These are an expansion of the ... care that is respectful of and responsive to ...
    (Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
    (Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
    (Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
    Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
    ... for women than men, major study finds , MONDAY, Aug. ... significantly increased risk for head and neck cancers such as ... and throat, says a U.S. National Cancer Institute study that ... women between 1995 and 2000. , The analysis revealed that ...
    ... the market in 2004 because they caused dangerous heart problems ... Hla at the University of Connecticut, may now have figured ... study will be published online in the The Journal of ... these drugs is an enzyme called COX-2, which is produced ...
    ... Smoking significantly increases the risk for head and neck ... anatomic site. Published in the October 1, 2007 issue ... Society, a large, prospective study confirmed strong associations between ... head and neck in both genders. , Cancers of ...
    ... of study to aid researchers in hunt for treatments ... public online database launched recently may help speed efforts ... bipolar disorder, a mood disorder commonly marked by alternating ... Disorder Phenome Database -- a joint project of the ...
    ... WESTCHESTER, Ill. For most children and teens, the beginning ... Not only will they be hitting the books again ... also participate in after-school activities. More research is emerging ... the number of children and teens who are considered obese ...
    ... study suggests that where the fat is stored is key ... a person is destined to develop diabetes, experiments in mice ... is stored. , Mice that overate and were very ... hormones let them store extra calories in fat tissue rather ...
    Cached Medicine News:Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 2Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 3Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 4Health News:Obesity Doesn't Always Equal Diabetes 2Health News:Obesity Doesn't Always Equal Diabetes 3
    ... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
    The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
    ... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
    ... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
    Medicine Products: